TP53-Mutated AML/MDS Patient Outcomes After Allogeneic Transplantation

A multi-center retrospective study analyzed 66 patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes who underwent allogeneic hematopoietic stem cell transplantation. Yao Sun authored this dataset, which includes endpoints for overall survival, progression-free survival, cumulative incidence of relapse, and non-relapse mortality. The dataset was last updated on May 6, 2026.

Use Cases

• Predicting overall survival based on genetic profiles and clinical characteristics mentioned in the description
• Analyzing progression-free survival patterns following transplantation
• Modeling the cumulative incidence of relapse using multivariate models
• Assessing non-relapse mortality risk through subgroup analyses

Strengths

• Includes data from 66 patients, providing a specific cohort size
• Analyzes multiple endpoints: OS, PFS, CIR, and NRM
• Utilizes subgroup analyses and multivariate models as described

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is 20.8 KB, indicating a very limited scope

Provenance

Source

figshare

Collection Method

Multi-center retrospective study

Freshness

Last updated 2026-05-06 00:10:09; freshness should be verified